Camila Vicencio Esguerra

Head of Group - Department of Pharmacy
Image of Camila Vicencio Esguerra
Norwegian version of this page
Phone +47 22840534
Visiting address Gaustadalléen 21 Forskningsparken 0349 Oslo
Postal address Postboks 1137 Blindern 0318 Oslo

Current Positions

12/2014 – present: Group Leader, Chemical Neuroscience Group, Biotechnology Centre of Oslo, Faculty of Medicine, University of Oslo

01/2015 - present: Adjunct Associate Professor, School of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo

Academic Interests

- Novel molecular mechanisms underlying neurological disorders (e.g. Epilepsy, Schizophrenia, Alzheimer´s)

  • Pharmacoresistance
  • Seizure initiation (ictogenesis)
  • Seizure progression (epileptogenesis)
  • Comorbidities (e.g. cognitive and locomotor impairment, SUDEP (Sudden Unexplained Death in Epilepsy Patients))

- Disease modeling in Zebrafish

- Influence of drug exposure on neural development

- Early-stage, preclinical drug discovery

  • Chemical Biology
  • In vivo, medium- to high-throughput chemical modifier screens
  • Natural product discovery
  • Pharmacological analysis of bioactive compounds
  • Toxicological assessment of drugs and potential therapeutic small-molecules
  • Mode of action/target identification of therapeutic lead compounds



University of Leuven, Leuven, Belgium:

10/2008 – 11/2014: 

  • Senior Scientist and Industrial Research Fellow, Laboratory for Molecular Biodiscovery, Department of Pharmaceutical Sciences and Pharmacology
  • Founder and Manager, Chemical Genetics Initiative @ KU Leuven
  • Project Coordinator, PharmaSea (EU FP7 Project, 2012-2014)                               

08/2006 – 01/2008:

  • Postdoctoral fellow, Laboratory of Catherine Verfaillie, Interdepartmental Stem Cell Institute                      

08/2006 – 01/2008:

  • Postdoctoral fellow, Laboratory of Frank Luyten, Laboratory for Skeletal Development and Joints, Department of Musculoskeletal Sciences                         

02/2003 – 04/2006: 

  • Senior Scientist and Doctoral Candidate, Laboratory of Desiré Collen, Molecular Cardiovascular Medicine Group, Faculty of Medical Sciences


2015 – present: 

Lecturer, School of Pharmacy, University of Oslo, Norway; Organic Chemically-Based Drug Design

01/2004 – 11/2014:

Lecturer, Biomedical Sciences Group, University of Leuven, Belgium; Principles of Genetics, Model Systems in Research, Laboratory Animal Science


02/2003-07/2007: Doctor of Medical Sciences (PhD), University of Leuven, Belgium

09/1992-08/1994: Master of Philosophy (MPhil) (Developmental Genetics)

  • Max Planck Institute for Developmental Biology, Tübingen, Germany
  • MRC National Institute for Medical Research, London, United Kingdom
  • Open University, Milton Keynes, United Kingdom

09/1986-06/1990: Bachelor of Arts in Biological Sciences (BA), Wellesley College, Wellesley, MA, USA

Current collaborations




Press clippings

Zebrafish; a see-though favourite with researchers (Uniforum, in Norwegian)



Selected publications (pdf)

Tags: Epilepsy, Genetics, Pharmacology


View all works in Cristin

  • Hultman, Maria Thérése; Christou, Maria; Rundberget, Jan Thomas; Esguerra, Camila Vicencio; Edhlund, Ian & Kamstra, Jorke Harmen [Show all 8 contributors for this article] (2021). Adverse outcome pathway (AOP) guided high-throughput in vitro and in vivo assessment of mitochondrial toxicants.
  • Song, You; Villeneuve, Daniel; Moe, Jannicke; Cao, Yang; Hultman, Maria Thérése & Christou, Maria [Show all 21 contributors for this article] (2021). Development of quantitative Adverse Outcome Pathways to facilitate next generation risk assessment of mitochondrial toxicants.
  • Song, You; Hultman, Maria Thérése; Moe, Jannicke; Petersen, Karina; Rundberget, Jan Thomas & Xie, Li [Show all 18 contributors for this article] (2020). The RiskAOP project - Quantitative Adverse Outcome Pathway assisted risk assessment of mitochondrial toxicants.
  • Banono, Nancy Saana; Gawel, Kinga Aurelia; De Witte, Linus & Esguerra, Camila (2020). Zebrafish larvae carrying a mutation in cacna1d display schizophrenia-like behaviours .

View all works in Cristin

Published Dec. 17, 2015 10:21 AM - Last modified July 26, 2022 2:17 PM

Research groups